RSV respiratory syncytial virus Archives

IDSA Concerned Over Federal Plan to Overhaul Infectious Disease Research

Sep 4, 2026 | Healthcare & Policy, Influenza, Other Infections

Leading medical societies warn that proposed changes and funding delays at the National Institutes of Health could disrupt active studies and patient care.

AAP Updates RSV, COVID-19 Vaccine Recommendations

Sep 3, 2026 | Coronavirus, Influenza, Neonatal, Pediatric Care, RSV

AAP recommendations expand second-season RSV protection criteria for children ages 8 to 19 months, alongside updated infant COVID-19 vaccination recommendations.

IDSA Issues Vaccine Recommendations for 2026-2027

Sep 3, 2026 | Coronavirus, Influenza, Other Infections, RSV

New clinical recommendations emphasize the safety and importance of COVID-19, influenza, and RSV vaccines for individuals with weakened immune systems.

Merck Wants to Extend RSV Vaccine to Second Season

Sep 2, 2026 | RSV, US Pharmaceuticals

FDA will review Enflonsia’s ability to protect high-risk children under 2 years of age during their second RSV season.

CVS, Walgreens Now Offering Seasonal Flu Vaccines

Aug 31, 2026 | Influenza, US Pharmaceuticals

CVS and Walgreens are expanding walk-in access, multi-vaccine scheduling, and respiratory illness testing ahead of peak viral activity.

NFID Initiative to Improve Respiratory Disease Prevention Messaging

Aug 18, 2026 | Coronavirus, Influenza, Other Infections, RSV

The National Foundation for Infectious Diseases (NFID) launched an initiative to streamline evidence-based information regarding respiratory disease prevention.

Co-Diagnostics Submits Co-Dx PCR Flu A/B & RSV Test for FDA Clearance

Aug 7, 2026 | Influenza, RSV, Testing

Co-Diagnostics submitted a dual 510(k) premarket notification and CLIA Waiver by Application to the FDA for its Co-Dx PCR Flu A/B & RSV multiplex respiratory test.

FDA to Review RSV Drug Enflonsia for Children 2 and Younger

Aug 6, 2026 | RSV, US Pharmaceuticals

Merck is seeking expand approval for its RSV drug Enflonsia to include children under age two through their second year of risk.

High RSV Hospitalization for Immunocompromised Adults

Jul 23, 2026 | RSV

Adults with weakened immune systems, particularly transplant recipients, face significant risks of severe illness and death from respiratory syncytial virus (RSV).

Child Respiratory Illnesses Linked to Lower Income, Educational Attainment

Jul 23, 2026 | Influenza, Neonatal, Other Infections, RSV

Infants exposed to viruses by older siblings face a higher risk of hospitalization and long-term socioeconomic challenges, according to new research.

COVID-19 Pandemic Shifted Timing of Seasonal Respiratory Surges

Jul 15, 2026 | Coronavirus, Influenza, RSV

A study shows that a loss of immunity caused flu and RSV peaks to occur earlier in the season before returning to pre-pandemic patterns.

RSV Antiviral Zelicapavir Enters Late-stage Clinical Trials

Jul 8, 2026 | Clinical Trials, RSV, US Pharmaceuticals

Enanta Pharma advanced zelicapavir into a registrational Phase 2b/3 clinical trial for adults at high risk of severe RSV outcomes.

FDA Clears AMDI Fast PCR Respiratory Panel for Point-of-Care Testing

Jul 1, 2026 | Coronavirus, FDA Approvals, Influenza, RSV, Testing

The AMDI Fast PCR System provides point-of-care results for RSV, influenza, and COVID-19 in less than 10 minutes.

Pediatric Risk Factors for Severe Respiratory Infections

Jun 10, 2026 | Influenza, Other Infections, Pediatric Care, RSV

Underlying chronic conditions and hospital transfers are major indicators of severe disease in pediatric patients with respiratory tract infections.

Maternal RSV Vaccine Cuts Infant Hospitalizations Nearly 70%

Jun 8, 2026 | Prenatal, RSV, US Pharmaceuticals

Real-world data published in JAMA Network Open confirm the effectiveness of the RSVpreF vaccine in protecting newborns from respiratory syncytial virus.

Lawsuit Alleges 1960s Infants Given RSV Vaccine Without Consent

May 28, 2026 | RSV

The families of two infants who died in the 1960s are suing the federal government alleging the babies received an experimental RSV vaccine without the knowledge or consent of their families, according to a report by The New York Times.

Maternal RSV Vaccination Cut Infant Hospitalization Risk by 80%

May 19, 2026 | Prenatal, RSV

Maternal RSV vaccination reduced infants’ hospitalization risk by more than 80% when administered at least 14 days before birth.

Enanta Pharma to Present Data for RSV, STAT6 Therapies at ATS 2026

May 14, 2026 | Clinical Trials, US Pharmaceuticals

Enanta Pharmaceuticals will present data on its RSV therapy zelicapavir and on EPS-3903, an oral STAT6 inhibitor, at ATS 2026.

Shared Bathroom Vents Linked to COVID-19 Aerosol Spread

May 12, 2026 | Coronavirus

Vertical ventilation ducts in residential buildings can facilitate the spread of infectious respiratory aerosols in multi-family buildings.

Phase II Trial for Antiviral Nasal Spray Advances to Next Stage

May 12, 2026 | Clinical Trials, US Pharmaceuticals

The once-weekly INNA-051 treatment from ENA Respiratory aims to prime the immune system to protect high-risk patients from influenza, RSV, and other respiratory viruses.